Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|April 11, 2016
Smoothing Relationships with Manufacturers in Specialty Pharmacy
Author(s)Davy James, Managing Editor
Marc O'Connor, chief operating officer of Curant Health, discusses efficiency in specialty pharmacy relationships.
Advertisement
Marc O'Connor, chief operating officer of Curant Health, discusses efficiency in specialty pharmacy relationships.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
4
Baseline Interferon Activity in Monocytes Predicts mRNA Vaccine Adverse Effects, Study Finds
5